Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHORD: DB-OTO intracochlear gene therapy in children with biallelic OTOF mutations
jRCT2033250730Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2026
- Modality
- Gene Therapies
01
Overview
Phase 2, open-label trial of lunsotogene parvec in congenital sensorineural hearing loss (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Achievement of a hearing sensitivity threshold of <=70 dB assessed by average pure tone audiometry (PTA). Started Apr 2026; status: recruiting.
02
Drugs
lunsotogene parvec
03
Conditions
congenital sensorineural hearing loss
Beyond the preview
Go deeper on jRCT2033250730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250730.